1. C. EVENO, S. GAUJOUX, G. TOBELEM, M. POCARD
   Did animal offer relevant model for bevacizumab testing
   BJC, 2008,  in press
   
   
2. P. FOUBERT, G. MATRONE, B. SOUTTOU, C. LERE-DEAN, V. BARATEAU, J. PLOUET, S. LE RICOUSSE-ROUSSANNE, B. LEVY, JS. SILVESTRE, G. TOBELEM
   Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy.
   Circulation Research, 2008, 103 :751-760
   
   
3. E. LEJMI, L. LECONTE, S. PEDRON-MAZOYER, S. ROPERT, W. RAOUL, S. LAVALETTE, I. BOURAS, JG FERON, M. MAITRE-BOUBE, F. ASSAYAG, C FEUMI, M. ALEMANY, TX. JIE, T. MERKULOVA-RAINON, MF POUPON, MM. RUCHOUX, G. TOBELEM, F. SENNLAUB, J. PLOUET
   Netrin-4 inhibits angiogenisis via binding to neogenin and recruitment of Unc5B.
   PNAS, 2008, 105 (34) : 12491-96
   
   
4. G. TOBELEM
   Les vaisseaux tumoraux : une cible thérapeutique majeure.
   STV, 2008 ; 5 (20) : 222-225
   
   
5. E. SULPICE, J. PLOUET, M. BERGE, D. ALLANIC, G. TOBELEM and T. MERKULOVA-RAINON
   Neuropilin-1 and neuropilin-2 as a coreceptors, potentiating proangiogenic activity.
   Blood 2008, 111 (4) : 2036-2045
   
   
6. J. ZOLL, V. FONTAINE, P. GOURDY, V. BARATEAU, J VILAR, A LEROYER, I. LOPES-KAM, Z. MALLAR, JF. ARNAL, P. HENRY, G. TOBELEM, A. TEDGUI
   Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition.
   Cardiovasc. Res. 2008 ; 77 : 471-480

1. S. LE RICOUSSE-ROUSSANNE, J. LARGHERO, JM. ZINI, V. BARATEAU, P. FOUBERT, G. UZAN, X. LIU, MN. LACASSAGNE, B. TERNAUX, I. ROBERT, M. BENBUNAN, JT. VILQUIN, K. VAUCHEZ, G. TOBELEM et JP. MAROLLEAU Ex vivo generation of mature and functional human smooth muscle cells differentiated from skeletal myoblasts. Experimental Cell Research 2007, 313 (7) : 1337-1346



2. P. FOUBERT, G. TOBELEM
   La thérapie cellulaire pro-angiogénique dans les pathologies ischémiques STV 2007 ; 6 (19) : 295-303



3. P. FOUBERT, G. TOBELEM
   La thérapie cellulaire pro-angiogénique dans les pathologies ischémiques Réflexions en Médecine Oncologique 2007 ; 18 (4) : 20-25



4. G. TOBELEM
   VEGF : a key therapeutic target for the treatment of cancer – insights into its role and pharmacological inhibition Targeted Oncology 2007 ; 2 : 153-164



5. P. FOUBERT, JS. SILVESTRE, B. SOUTTOU, V. BARATEAU, C. MARTIN, TG. EBRAHIMIAN, C LERE-DEAN, JO CONTRERES, E. SULPICE, BI. LEVY, J. PLOUET, G. TOBELEM, S. LE RICOUSSE-ROUSSANNE Activation of EphB4 increases pro-angiogenic potential of endothelial progenitor cells. Role of P-selectin glycoprotein ligand-1. J Clin Invest. 2007, 117 (6) : 1527-1537



6. P. BONNIN, A. VILLEMAIN, F. VINCENT, H. DEBBABI, JS. SILVESTRE, JO. CONTRERES, BI. LEVY, G. TOBELEM, E. DUPUY Ultrasonic assessment of hepatic blood flow as a marker of mouse hepatocarcinoma.
   Ultrasound in med and Biol 2007 ; 33 (4) : 561-570

1. C. CHAABANE, E. CORVAZIER, R. BREDOUX, S. DALLY, AL. RAIES, A. VILLEMAIN, E. DUPUY, J. ENOUF et R. BOBE
   Sarco/endoplasmic reticulum Ca2+ ATPase type 3 isoforms (SERCA3b ans SERCA3f) : Distinct roles in cell adhesion and ER stress.
   BBRC 2006 ; 345 : 1377-1385

 

2. S. ROPERT, J. PLOUET
   VEGF as a target.
   Targeted Oncology, 2006 ; 4 : 239-240

 

3. P. FONS, S. CHABOT, JE CARTWRIGHT, F. LENFANT, F. L'FAQIHI, J. GIUSTINIANI, JP HERAULT, G. GUEGUEN, F. BONO, P. SAVI, M. AGUERRE-GIRR, S. FOURNEL, F. MALECAZE, A. BENSUSSAN, J. PLOUET, P. LE BOUTEILLER
   Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells.
   Blood 2006 ; oct 15 ; 108 (8) : 2608-15

 

4. J. PLOUET
   Inhibiting angiogenesis : interview with Dr Jean Plouet. Interview by Emma Quiegley.
   Expert Opin Ther Targets 2006 ; Aug ; 10(4) : 501-3

 

5. S. PEDRON-MAZOYER, J. PLOUET, L. HELLAUDAIS, J. TEISSIE, M. GOLZIO.
   New anti angiogenesis developments through electro-immunization : Optimization by in vivo optical imaging of intradermal electrogenetransfer.
   Biochim Biophys Acta 2006 ; sept. 29

 

6. X. DRAY, X. TRETON, MC. MAZERON, A. LAVERGNE-SLOVE, F. JOLY, D. MIMRAM, A. ATTAR, G. TOBELEM, Y. BOUHNIK
   Herpes simplex virus type 1 colitis in a patient with common variable immunodeficiency syndrome.
   Eur J Gastroenterol Hepatol 2006 ; 18(5) : 541-544

 

7. L. WAECKEL, J. BIGNON, JM.LIU, D. MARKOVITS, TG. EBRAHIMIAN, J. VILAR, O. BLANC-BRUDE, V. BARATEAU, S. LE RICOUSSE-ROUSSANNE, M. DURIEZ , G. TOBELEM, J. WDZIECZACK-BAKALA, B. LEVY,JS. SILVESTRE
   Tetrapeptide AcSDKP induces post-ischemic neovascularization through monocyte chemoattractant protein-1 signaling.
   Art. Thromb. Vasc. Biology 2006 ; 26 : 773-779

 

8. P. HAINAUD, JO. CONTRERES, A. VILLEMAIN, LX. LIU, J. PLOUET, G. TOBELEM and E. DUPUY
   The role of the Vascular endothelial growth factor-delta-like 4 ligand/notch4-ephrin B2 cascade in tumor vessel. Remodeling and endothelial cell functions.
   Cancer Res 2006 ; 66 : 8501-8510

 

9. D. YOU, L. WAECKEL, TG. EBRAHIMIAN, O. BLANC-BRUDE, P. FOUBERT, M. DURIEZ, S. LE RICOUSSE-ROUSSANE, J. VILAR, E. DEJANA, G. TOBELEM, B. LEVY, JS. SILVESTRE
   Increase in vascular permeability and vasodilation are critical for pro-angiogenic effects of stem cell therapy.
   Circulation 2006 ; 114 : 328-338

 

10. H. CHEDANI, E. DUPUY, JM. MASSE et EM. CRAMER
    Neutrophil secretory defect in the gray platelet syndrome : a new case.
    Platelets february 2006 ; 17(I) : 14-19

1. S. BELLUCCI, MG. HUISSE, B. BOVAL, P. HAINAUD, A. ROBERT, F. FAUVEL LAFEVE, M. JANDROT PERRUS
   Defective collagen-induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI- coupled signalling pathway.
   Thromb. Haemost 2005 ; 93 : 130-138

1. E. SULPICE, JO. CONTRERES, J. LACOUR, M. BRYCKAERT and G. TOBELEM
   Platelet factor 4 disrupts the intracellular signalling cascade induced by VEGF by both KDR dependent and independent mechanisms.
   Eur. J. Biochem., 2004 ; 271 : 3310-3318

 

2. S. LE RICOUSSE-ROUSSANNE, V. BARATEAU, JO. CONTRERES, B. BOVAL, L. KRAUS-BERTHIER, G. TOBELEM
   Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature.
   Cardiovascular Research 2004 ; 62 : 176-184

 

3. R. TAMARAT, JS. SILVESTRE, S. LE RICOUSSE-ROUSSANNE, V. BARATEAU, L. LECOMTE-RACLET, M. CLERGUE, M. DURIEZ, G. TOBELEM, B. LEVY
   Impairement in ischemia-induced neovascularization in diabetes : bone marrow mononuclear cells dysfunctions and therapeutic potential of PIGF treatment.
   American Journal of pathology 2004 ; 2 : 457-466

 
2003 :

1. G. TOBELEM
   Angiogenèse tumorale : faits et espoirs.
   STV 2003 ; 9-10 : 481-485

 
 

2. JS. SILVESTRE, A. GOJOVA, S. POTTEAUX, B. ESPOSITO, M. DURIEZ, M. CLERGUE, S. LE RICOUSSE-ROUSSANNE, V. BARATEAU, G. TOBELEM, B. LEVY, A. TEDGUI, Z. MALLAT
   Transplantation of bone marrow-derived mononuclear cells in ischemic apoE knockout mice accelerates atherosclerosis without altering plaque composition.
   Circulation 2003 ; 108 : 2839-2842

 

3. R. HE, B. LIU, C. YANG, RC. YANG, G. TOBELEM, ZC. HAN
   Inhibition of K 562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence.
   Cancer Gene Therapy 2003 ; 10 : 879-886

 

4. Y. LI, Y. JIN, H. CHEN, G. JIE, G. TOBELEM, J. CAEN, Z.C. HAN
   Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4.
   Cancer Biother Radiopharm 2003 ; 18 : 829-840

 

5. E. DUPUY, A. HABIB, M. LEBRET, R. YANG, S. LEVY-TOLEDANO and G. TOBELEM
   Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells. Possible relevance to HIF-1 a
   Journal of thrombosis and haemostasis 2003 ; 1 : 1096-1102

 

6. T. MERKULOVA-RAINON, P. ENGLAND, S. DING, C. DEMERENS and G. TOBELEM
   The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor.
   J. Biol. Chem 2003 ; 39 : 37400-37408

 

7. E. DUPUY et G. TOBELEM
   Mécanismes de la lymphangiogenèse tumorale, longtemps oubliée, dans la dissémination métastatique.
   Bull Cancer 2003 ; 90 : 595-599

 

8. E. DUPUY, P. HAINAUD, A. VILLEMAIN, E. BODEVIN-PHEDRE, P. BRIAND and G. TOBELEM
   Tumoral angiogenesis and tissue factor expression during hepatocarcinoma progression in a transgenic mouse model
   Journal of hepatology 2003 ; 38 : 793-802

 

9. S. DING, T. MERKULOVA-RAINON, ZC. HAN and G. TOBELEM
   HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro.
   Blood 2003 ; 12 : 4816-4822

 

10. P. LIU, Y. WANG, Y. LI, C. YANG, Y. ZHOU, B. LI, S. LU, R. YANG, Y. CAI, G. TOBELEM, J. CAEN, ZC. HAN
    Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukaemia xenograft groxth in nude mice.
    Leukemia Research 2003 ; 27 : 701-708

 

11. S. ROSENSTINGL, JP. BROULAND, JM. ZINI, G. TOBELEM, E. DUPUY
    Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis : the role of megakaryocytes.
    Acta Haematologica 2003 ; 109 : 145-149

 
2002 :

1. P. HAINAUD, JP. BROULAND, P. ANDRE, G. SIMONEAU, C. BAL DIT SOLLIER, L. DROUET, J. CAEN and S. BELLUCCI
   Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia : studies in an ex vivo perfusion chamber model.
   British Journal of Haematology 2002 ; 119 : 998-1004

 

2. G. TOBELEM
   Les antithrombines directes : du concept au développement.
   STV 2002 ; 9-10 : 515-521

 

3. Z. MALLAT, JS. SILVESTRE, S. LE RICOUSSE-ROUSSANNE, L. LECOMTE-RACLET, A. CORBAZ, M. CLERGUE, M. DURIEZ, V. BARATEAU, A. TEDGUI, G. TOBELEM, Y. CHVATCHKO, B. LEVY
   Interleukin (IL)-18/IL-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb.
   Circulation Research 2002 ; 91 : 441-448

 

4. E. SULPICE, M. BRYCKAERT, J. LACOUR, JO. CONTRERES, G. TOBELEM
   Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.
   Blood 2002 ; 9 : 3087-3094

1. G. TOBELEM
   Les cellules souches vasculaires : une nouvelle étape vers la régénération des vaisseaux.
   STV 2001 ; 10 : 521-528

 

2. E. DUPUY, C. SORIA, P. MOLHO, JM. ZINI, C. LAURIAN, P. BRUNEVAL, G. TOBELEM
   Embolized ischemic lesions of toes in a young afibrinogenemic patient : possible relevance to in vivo circulating thrombin.
   Thrombosis Research 2001 ; 102 : 211-219
   
3. S. ROSENSTINGL, E. DUPUY, O. ALVES, B. GEORGES, G. TOBELEM
   Maladie de Behçet révélée par un anévrisme intracrânien.
   Rev Méd Interne 2001 ; 22 : 177-182

 

4. P. HAINAUD, M. BONNEAU, G. PIGNAUD, C. BAL DIT SOLLIER, P. ANDRE, P. HADJIISKY, JP. FIEFFE, JP. CAEN, JM. HERBERT, F. DOL, LO. DROUET
   The calcium inhibitor SR 33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis 2001 ; 154 : 301-308

1. G. TOBELEM
   L'angiogenèse thérapeutique : vers une longue route difficile.
   STV 2000 ; 10 : 591-597

 

2. F. GANNE, M. VASSE, JL. BEAUDEUX, J. PEYNET, A. FRANCOIS, Z. MISHAL, A. CHARTIER, G.TOBELEM, JP. VANNIER, J. SORIA, C. SORIA
   Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes. A possible protective mechanism against atherothrombosis.
   Thrombosis Haemostasis 2000 ; 84 : 680-688

 

3. L. LECOMTE-RACLET, M. RHOLAM, M. ALEMANY, N. LAZAR, C. SIMENEL, M. DELEPIERRE, ZC. HAN, P. COHEN, J.CAEN
   Dual structural requirements for multilineage hematopoietic-suppressive activity of chemokine derived peptides.
   Biochemistry 2000 ; 31 : 9612-9622

1999 :

1. E. MAZOYER, L. DROUET, C. SORIA, JC. FRUCHART, A. PELLERIN, JC. ARCAN and G. TOBELEM Risk factors and outcomes for atherothrombotic disease in french patients : the RIVAGE study. Thrombosis Research 1999 ; 95 : 163-176